VESICULAR STOMATITIS VIRUS FOR PRIME BOOST VACCINES

摘要

The present invention relates to a matrix (M) protein mutation of vesicular stomatitis virus (VSV). One mutant M protein includes glycine changed from glutamic acid at position 21, leucine changed from phenyl at position 111 to methionine, and methionine changed from position 51 to arginine. The other M protein mutation includes glycine changed to glutamic acid at position (22) and methionine changed to arginine at positions (48 and 51). Another M protein mutation includes glycine changed to glutamic acid at position (22), leucine changed to phenylalanine at position (110), and methionine changed to arginine at positions (48 and 51). The present invention also relates to recombinant VSV (rVSV) with this M mutation and to rVSV based vaccines with the M mutant of the invention. This new rVSV with mutant M is largely attenuated, including neurotoxic, toxic, highly attenuated, non-toxic, and can induce an immune response to the antigen of interest. In addition, the rVSV serotype Indiana with the first-mentioned M mutation can be efficiently replicated at 31 ° C and not replicated or replicated poorly at temperatures above approximately 37 ° C.